Answers are grounded in this paper and cite their sources.
Due to the energy-dense but nutrient-deficient diets, sedentary lifestyle and lack of exercise as well as an aging population, the prevalence and incidence of overweight/ obesity/sarcopenic obesity, type 2 diabetes mellitus (T2DM), metabolic syndrome and their related non-alcoholic fatty liver disease (NAFLD) have been increasing globally in the last two decades.In Europe and the United States, NAFLD has become the second leading cause of endstage liver disease and liver transplantation (1).Worse still, the onset age of NAFLD is becoming younger tendency.Although the new nomenclature of metabolic dysfunctionassociated fatty liver disease (MAFLD) has been proposed for 3 years, MAFLD is not equivalent to NAFLD, and few epidemiologic investigations on MAFLD to date.Therefore, this invited editorial is focus on the global epidemiology of NAFLD and the major impact on China. Global epidemiology of NAFLDRiazi et al. (2) conducted a systematic review and metaanalysis of 72 studies with a total of 1,030,160 respondents in 17 countries worldwide by May 25, 2021, and found that the overall global prevalence of NAFLD was estimated to be 32.4% [95% confidence interval (CI): 29.9-34.9%],significantly higher in men (39.7%) than women (25.6%).The overall NAFLD prevalence increased over time, from 25.5% in or before 2005 to 37.8% in 2016 or later.A metaanalysis from Younossi et al. (3) reported that the overall global prevalence of NAFLD was highest in Latin America (44.37%), followed by the Middle East and North Africa, South Asia, South-East Asia, North America, East Asia, and lowest in Western Europe (25.10%)(Figure 1A).The systematic review and meta-analysis by Quek et al. (4) included 151 studies from 2000 to 2022 with 101,028 adults enrolled, which revealed that the prevalence rate of NAFLD, non-alcoholic fatty liver (NAFL), and nonalcoholic steatohepatitis (NASH) in the overweight group was 70.0%, 42.5% and 33.5%, respectively, and the rate was 75.3%, 43.1% and 33.7% among the obese group (Figure 1B); the proportion of significant fibrosis in overweight and obese patients with NAFLD was 20.3% and 21.6%, respectively, and the proportion of advanced fibrosis was 6.7% and 6.9%, respectively.Another meta-analysis by Younossi et al. (5) included 80 studies from 20 countries with a total of 49,419 patients with T2DM, and the results showed that the overall prevalence of NAFLD and NASH was 55.5% (95% CI: 47.3-63.7%)and 37.3% (95% CI: 24.7-50.0%),respectively; and the prevalence of advanced fibrosis was 17.0% (95% CI: 7.2-34.8%) in diabetic patients with NAFLD (Figure 1C).
No takes yet. Share an insight, caveat, or question.
Lou et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: